Fairmount Funds Management Llc
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$1.38B
Q ending 2026-03-31
Prior quarter
$1.31B
Q ending 2025-12-31
Change
+5.4% QoQ · +114.8% YoY
Positions
12
reported holdings
Largest positions
All 12 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Damora Therapeutics Inc | DMRA | Shares | $225.7M | 8.7M |
| Dianthus Therapeutics Inc | DNTH | Shares | $212.9M | 2.5M |
| Cogent Biosciences Inc | COGT | Shares | $211.8M | 5.5M |
| Spyre Therapeutics Inc | SYRE | Shares | $202.7M | 4.0M |
| Oruka Therapeutics Inc | ORKA | Shares | $181.7M | 3.7M |
| Viridian Therapeutics Inc | VRDN | Shares | $76.6M | 3.9M |
| Enliven Therapeutics Inc | ELVN | Shares | $72.7M | 1.9M |
| Jade Biosciences Inc | JBIO | Shares | $64.0M | 4.6M |
| Crescent Biopharma Inc. | Shares | $50.5M | 2.7M | |
| Zenas Biopharma Inc | ZBIO | Shares | $46.1M | 2.4M |
| Apogee Therapeutics Inc | APGE | Shares | $25.1M | 299K |
| Inhibikase Therapeutics Inc | IKT | Shares | $14.5M | 8.6M |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.